Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
University of Maryland, Baltimore · Cleveland Clinic · +14 more institutions
Abstract
Grade 2 gliomas occur most commonly in young adults and cause progressive neurologic deterioration and premature death. Early results of this trial showed that treatment with procarbazine, lomustine (also called CCNU), and vincristine after radiation therapy at the time of initial diagnosis resulted in longer progression-free survival, but not overall survival, than radiation therapy alone. We now report the long-term results.
We included patients with grade 2 astrocytoma, oligoastrocytoma, or oligodendroglioma who were younger than 40 years of age and had undergone subtotal resection or biopsy or who were 40 years of age or older and had undergone biopsy or resection of any of the tumor. Patients were stratified according to age, histologic findings, Karnofsky performance-status score, and presence or absence of contrast enhancement on preoperative images. Patients were randomly assigned to radiation therapy alone or to radiation therapy followed by six cycles of combination chemotherapy.
Citation impact
- FWCI
- 80.64
- Percentile
- 100%
- References
- 18
Authors
22- JCJan C. BucknerCorresponding
University of Maryland, Baltimore, Cleveland Clinic, Mayo Clinic in Arizona
- EGEdward G. Shaw
University of Maryland, Baltimore, Cleveland Clinic, Wake Forest University
- SLStephanie L. Pugh
University of Maryland, Baltimore, Cleveland Clinic, NRG Oncology
- ACArnab Chakravarti
University of Maryland, Baltimore, Cleveland Clinic, The Ohio State University
- MRMark R. Gilbert
University of Maryland, Baltimore, Cleveland Clinic, The University of Texas MD Anderson Cancer Center
Topics & keywords
- Medicine
- Procarbazine
- Lomustine
- Vincristine
- Radiation therapy
- Oligodendroglioma
- Surgery
- Chemotherapy
- Good health and well-being